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Available online 10 November 2016Background:We present the results of a Phase 2a randomized controlled trial investigating the safety, and sec-
ondary endpoints of subretinal rAAV.sFLT-1 gene therapy in patients with activewet age-relatedmacular degen-
eration (wAMD).
Methods: All patients (n = 32), (ClinicalTrials.gov; NCT01494805), received ranibizumab injections at baseline
and week 4, and thereafter according to prespeciﬁed criteria. Patients in the gene therapy group (n = 21) re-
ceived rAAV.sFLT-1 (1 × 1011 vg). All patients were assessed every 4 weeks to the week 52 primary endpoint.
Findings:Ocular adverse events (AEs) in the rAAV.sFLT-1 groupweremainly procedure related and self-resolved.
All 11 phakic patients in the rAAV.sFLT-1 group showed progression of cataract following vitrectomy. No system-
ic safety signals were observed and none of the serious AEs were associated with rAAV.sFLT-1. AAV2 capsid was
not detected and rAAV.sFLT-1 DNA was detected transiently in the tears of 13 patients. ELISPOT analysis did not
identify any notable changes in T-cell response. In the rAAV.sFLT-1 group 12 patients had neutralizing antibodies
(nAb) to AAV2. There was no change in sFLT-1 levels in bodily ﬂuids. In the rAAV.sFLT-1 group, Best Corrected
Visual Acuity (BCVA) improved by a median of 1.0 (IQR: −3.0 to 9.0) Early Treatment Diabetic Retinopathy
Study (ETDRS) letters from baseline compared to a median of−5.0 (IQR:−17.5 to 1.0) ETDRS letters change
in the control group. Twelve (57%) patients in the rAAV.sFLT-1 group maintained or improved vision compared
to 4 (36%) in the control group. Themedian number of ranibizumab retreatmentswas 2.0 (IQR: 1.0 to 6.0) for the
gene therapy group compared to 4.0 (IQR: 3.5 to 4.0) for the control group.
Interpretation rAAV.sFLT-1 combined with the option for co-treatment appears to be a safe and promising ap-
proach to the treatment of wAMD.
Funding:National Health andMedical Research Council of Australia (AP1010405), Lions Eye Institute, Perth Aus-
tralia, Avalanche Biotechnologies, Menlo Pk, CA, USA.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Clinical trial1. Introduction
Age-related macular degeneration (AMD) is a common cause of vi-
sion loss in the elderly (Congdon et al., 2004). The role of vascular endo-
thelial growth factor (VEGF) in the pathogenesis of the neovascular
form of AMD, wet AMD (wAMD), is well established (Kliffen et al.,logy and Visual Science, The
akoczy).
. This is an open access article under1997), and the efﬁcacy of anti-VEGF molecules such as ranibizumab,
bevacizumab and aﬂibercept in treating wAMD has been extensively
studied (Kaiser et al., 2007; Rosenfeld et al., 2006; Schmidt-Erfurth et
al., 2014). More recently, down-regulation of naturally occurring anti-
angiogenic factors such as pigment epithelium-derived factor (PEDF)
and soluble fms-like tyrosine kinase-1 (sFLT-1) in wAMD has been
found to exacerbate the degenerative process (Bouck, 2002; Luo et al.,
2013; Ohno-Matsui et al., 2001).
The advent of recombinant adeno-associated virus (rAAV) vector
gene-therapy has enabled exploration of treatments with the potentialthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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2015). rAAV vectors have been studied in individuals with monogenic
conditions, such as choroideremia (Vasireddy et al., 2013), Leber's con-
genital amaurosis (LCA) (Maguire et al., 2008), and X-linked retinoschi-
sis (XLRS). Further, the potential to deliver long-term, stable protein
expression via gene therapy intraocularly to treat a complex disease
like wAMD creates the possibility of a paradigm shift in the delivery of
ophthalmic healthcare.
sFLT-1 is a naturally occurringVEGF inhibitor that is a soluble variant
of the full length membrane bound VEGFR-1 protein (Kendall and
Thomas, 1993). It has been reported that serum sFLT-1 is lower in
wAMD patients (Uehara et al., 2015) and that sFLT-1 alone is sufﬁcient
to confer protection against choroidal neovascularization (CNV) in ro-
dent and primate models (Lai et al., 2001; Lai et al., 2012; Lai et al.,
2009; Lai et al., 2005; Lai et al., 2002; Rakoczy et al., 2015). Recombinant
vector mediated gene delivery using subretinal injection of rAAV.sFLT-1
has been one approach used to demonstrate this (Lai et al., 2001; Lai et
al., 2012; Lai et al., 2009; Lai et al., 2005; Lai et al., 2003; Lai et al., 2002;
Rakoczy et al., 2015). This allows for the vector to be placed directly ad-
jacent to the retinal pigment epithelial (RPE) cells and photoreceptors,
enabling uptake and transduction of the viral vector. The expression of
sFLT-1 is then accomplished through the normal protein-producingma-
chinery of the host cells.
We previously published our ﬁndings on the safety of rAAV.sFLT-
1 administered subretinally to 6 patients with advanced wAMD in a
Phase 1 trial (Rakoczy et al., 2015) (www.youtube.com/watch?v=
CUiSFAi2_EY). Here, we present the results of our Phase 2a random-
ized clinical trial, investigating the safety, immunologic and other
secondary endpoints of rAAV.sFLT-1 gene therapy delivered
subretinally to 21 patients with active wAMD compared to 11 con-
trol patients.Fig. 1. Trial proﬁle for Phase 1 (Rakoczy et2. Methods
The design and methods of the study were previously described in
detail (Rakoczy et al., 2015) and they are summarized as follows:
2.1. Study Design
The primary objective of the studywas to assess the safety and toler-
ability of rAAV.sFLT-1 in subjectswithwAMD. This Phase 2a studywas a
single center, investigator-sponsored trial registered at ClinicalTrials.
gov; NCT01494805 (Rakoczy et al., 2015). Patients were recruited
from the Lions Eye Institute (LEI), Nedlands, WA, Australia and Sir
Charles Gairdner Hospital (SCGH) Nedlands, WA, Australia. This study
involved 32 patients with active wAMD who received either
rAAV.sFLT-1, 1 × 1011 vg subretinally (N = 21), and/or intravitreal
ranibizumab pro re nata (PRN) (Fig. 1). Patients were assessed every
4 weeks to the week 52 primary endpoint, with long-term follow-up
to continue through to 36 months. Any ocular or systemic adverse
events (AEs) were reported to the principal investigator (IJC) who de-
terminedwhether theywere related to gene therapy, ranibizumab ther-
apy, study procedures, or unrelated. Gene therapy patients had all AEs
over the 52-week duration recorded in the case report form (CRF),
whereas in control patients AEs were recorded in the CRF for up to
30 days after which only AEs deemed related to study procedures, in-
cluding ranibizumab injections, were recorded. Serious AEs (SAEs) in
both groups were reported for the duration of the study and followed
up until resolution.
The protocol was approved by the Australian Therapeutic Goods Ad-
ministration. The trial was performed at the LEI. Approval was obtained
from The University of Western Australia Institutional Biosafety Com-
mittee and the SCGH Human Ethics Committee. The tenets of theal., 2015) and Phase 2a clinical trials.
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informed consent.2.2. Participants
Eligibility criteria included patients 55 years or older, with a best
corrected visual acuity (BCVA) worse than 20/40 secondary to wAMD
due to active subfoveal choroidal CNVdemonstrated by leakage onﬂuo-
rescein angiography (FA), or the presence of ﬂuid on spectral domain
optical coherence tomography (SD-OCT). The vast majority of patients
had previously received anti-VEGF therapy, and a washout period for
the anti-VEGF was not required prior to the baseline visit.2.3. Randomization and Masking
Since this was a Phase 2a study, no power calculation was done to
determine sample size. The patients were randomized in a 2:1 ratio
(gene therapy: control) according to a computer-generated permuted
block randomization list prepared at the start of the study and held
off-site. The procedure staff and patients were not masked to the treat-
ment received. Staff members performing the assessments at study
visits were masked to the study group.2.4. Procedures
The subretinal gene-therapy delivery procedure was described pre-
viously in the Phase 1 study (Rakoczy et al., 2015). All 32 patients re-
ceived intravitreal 0·5 mg ranibizumab in the study eye at baseline
and at the week 4 visit. The patients in the gene therapy group received
subretinal injection of 100 μL rAAV.sFLT-1 (1× 1011 vg) following a core
vitrectomy at day 7. Primary and secondary end points were
preselected. The primary end point was measured using physical and
ophthalmic examinations, vital signs and clinical laboratory testing.
Study assessments included ophthalmic examination, BCVA, and SD-
OCT every 4 weeks. FA was performed quarterly. Ranibizumab
retreatment was indicated for worsening disease: N10 Early Treatment
Diabetic Retinopathy Study (ETDRS) letter loss (from patient's previous
visit) attributable to CNV or N5 EDTRS letter loss if apparent to the pa-
tient, any increased, new or persistent subsensory, sub-RPE, or
intraretinal ﬂuid on SD-OCT N50 μm from previous visit, or signs of in-
creased CNV leakage on FA. Laboratory tests included routine hematol-
ogy, renal and hepatic function tests, urine protein, serum IgM, IgG, IgA
levels and protein electrophoresis, and enumeration of peripheral blood
lymphocyte subsets (B cells - CD19+; T cells - CD3+, CD4+, CD8+;
and natural killer cells - CD3−, CD16+, CD56+). Biodistribution of
rAAV.sFLT-1 was assessed by qPCR for rAAV.sFLT-1 DNA and AAV2 cap-
sid detection by ELISA in tears from treated and fellow eye, serum, urine,
and saliva. AAV2-speciﬁc immune responses assessed included neutral-
izing antibodies (nAb), total antibodies to AAV2 capsid proteins detect-
ed by ELISA and AAV2-speciﬁc T-cells detected by interferon-gamma
(IFN-γ) ELISpot assay.Table 1
Baseline characteristics of Phase 2a patients.
Active Control All patients
N = 21 N = 11 N = 32
Age (years), median (Q1, Q3) 80 (73, 81) 79 (77, 83) 80 (74, 83)
Baseline BCVA (ETDRS letters), median
(Q1, Q3)
63 (50, 71) 63 (53, 69) 63 (50, 70)
Baseline center point thickness (μm),
median (Q1, Q3)
328 (285,
388)
349 (307,
515)
333
(296,460)
Number treatment naïve 1 (5%) 2 (18%) 3 (9%)
Previous anti-VEGF injections, median
(Q1, Q3)
10 (5,13) 8 (3,24) 9 (5,14)
Fibrosis at baseline 17 (81%) 10 (91%) 27 (84%)
PED at baseline 7 (33%) 4 (36%) 11 (34%)2.5. Outcomes
This study was primarily designed to assess the safety and tolerabil-
ity of rAAV.sFLT-1 in patients withwAMD. Secondary objectiveswere to
assess the effect of rAAV.sFLT-1 using analysis of BCVA, number of
ranibizumab retreatments received, and retinal thickness on SD-OCT.
There were no speciﬁc data exclusion criteria used. Biodistribution of
rAAV.sFLT-1 and the immune response to AAV2 were also assessed. A
further post hoc analysis of the fundus photographs, ﬂuorescein angio-
grams, and SD-OCT images for each patient was completed by the
Doheny Image Reading Center (DIRC), Los Angeles, USA.2.6. Statistical Analysis
The primary analysis was conducted whenweek 52 data were avail-
able and locked for all patients. LEI transferred the data to CPR Pharma
Services PTY LTF (Therbarton, Australia). Safety analyzes were conduct-
ed according to the randomized treatment group. There were no specif-
ic treatments for outliers. Comparisons between groups were
performed using t-tests, Wilcoxon rank sum tests, and Fisher's exact
tests as appropriate for each endpoint. Analyzes were conducted using
SAS software, version 9·4 (SAS Institute, Inc.) or “R”-statistics.
3. Results
3.1. Disposition
Between August 2012 andMarch 2014, 32 patients were enrolled in
this Phase 2a study and all completed 52 weeks of follow-up.
3.2. Demographics
The patient cohort was 97% (31) white and 63% (20) female, with a
median age of 80.0 years (IQR: 74.0 to 83.0). The Phase 2a patients were
similar in age to the Phase 1 patients (Rakoczy et al., 2015), but had less
advanced although still activewAMD in the study eye (Table S1). Twen-
ty-nine Phase 2a patients were previously treated for wAMD and 3 (1
gene therapy, 2 controls) were treatment-naïve patients. Within the
Phase 2a study, the active and control armswere otherwise comparable
in terms of age, BCVA and other ocular parameters (Table 1).
3.3. Primary Endpoint: Safety
3.3.1. Ocular Safety
No serious ocular AE was reported in the gene therapy group and 1
endophthalmitis event was reported in the control group (Table S2).
There were 51 ocular AEs in the rAAV.sFLT-1 group which included
subconjunctival (10), minor subretinal (8) or vitreous hemorrhage (4)
and anterior chamber inﬂammation/uveitis (3). Twenty-six (51·0%) of
these AEs were related to the study procedure and occurred within
30 days post administration (Table S3). The majority of cases were
deemed to be mild in nature, visually insigniﬁcant with no permanent
sequelae. Two ocular AEs were considered possibly related to
rAAV.sFLT-1 were eye inﬂammation, and anterior chamber inﬂamma-
tion, which were mild in nature and resolved without sequelae. As ex-
pected in this age group, visually signiﬁcant nuclear cataract
developed in all phakic patients (n = 11) following vitrectomy. One
case of signiﬁcant vision loss (≥15 ETDRS letters) at week 52 was ob-
served in the gene therapy group and was attributed to progression of
wAMD.
The control group had 3 cases of signiﬁcant vision loss (≥15 ETDRS
letters) at week 52. One case was attributed to endophthalmitis 3 days
after an intravitreal ranibizumab injection, the second to a large
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The control group also reported one case each of posterior vitreous de-
tachment, corneal opacities, and cataract (Table S3). Of the 11 controls,
7 were phakic. One had cataract removed at 9 months following en-
dophthalmitis treated with vitrectomy.
3.3.2. Systemic Safety
No systemic safety signals were observed relative to treatment.
None of the 7 SAEs in the gene therapy group were attributed to
rAAV.sFLT-1 gene therapy (Table S2) and no clinically signiﬁcant abnor-
malities in laboratory tests values were reported. Two transient labora-
tory AEs normalized to within reference range by the following visit
were deemed by the investigator (IJC) to be possibly but not likely relat-
ed to gene therapy. Over the 52 weeks follow up, all other non-ocular
AEs were classiﬁed as mild or moderate and were deemed unrelated
to the study procedure (Table S3). The most commonly reported non-
ocular AEs involved the respiratory system. In the gene therapy group
therewere 4 episodes of upper respiratory tract infection (URTI, 2 unde-
ﬁned, 1 sinusitis and 1 nasopharyngitis) and 2 episodes of lower respi-
ratory tract infection (LRTI). These respiratory tract infections were
mild and self-limiting and occurred between 75 and 358 days post en-
tering the trial, without any trend. OneURTI and one LRTIwere reported
prior to receiving rAAV.sFLT-1 at baseline and at day 19 after gene ther-
apy, respectively. In the control group there were 4 AEs with an infec-
tious nature, including 2 URTI (1 undeﬁned and 1 sinusitis). Other
non-ocular adverse events in both groups were deemed unrelated to
the study procedure (Table S3).
3.4. Biodistribution
AAV2 capsidwas not detected in samples collected at any timepoint.
In the gene therapy group, rAAV.sFLT-1 DNAwas detected transiently in
the tears from the treated eye in a subset of patients (13/21), in the tears
of the fellow eye in one patient, in the saliva in one patient, and in the
urine in one patient. All these occurrences resolved prior to the week
4 visit and none of the patients had detectable vector DNA in blood
(Table S4). The measured systemic levels of sFLT-1 and VEGF proteins
in serum, saliva, and urine did not show any statistically signiﬁcant dif-
ference at baseline between the control and gene therapy group. There
was also no statically signiﬁcant difference between the sFLT-1 and
VEGF levels at baseline andweek 52 of the gene therapy group. The lim-
ited number of vitreous samples did not show any change in sFLT-1 pro-
tein levels between the baseline and week 4 (Table S5).
3.5. Immune Response to AAV2
At baseline 9 of 21 rAAV.sFLT-1-injected patients had no detectable
nAbs to AAV2, 5 patients had low nAb titre (1:20–1:100) and 7 patients
had nAb titres (N1:100). Three of the 9 nAb-negative patients
seroconverted after rAAV.sFLT-1 therapy. Serum levels of antibodies to
AAV2 capsid proteins were variable and uninformative. Enumeration
of AAV2-speciﬁc T-cells in peripheral bloodmononuclear cells, as deter-
mined by IFN-γ ELISpot assay, demonstrated that therewere no notable
changes in T-cell responses to AAV2 during the study period in all, but 1
patient who exhibited elevated responses at random multiple time
points post-treatment.
3.6. Secondary Endpoints and Post Hoc Analysis
3.6.1. BCVA
In the gene therapy group (n=21), themedian change in BCVAwas
1.0 (IQR:−3.0 to 9.0) ETDRS letters from baseline (median: 63.0, IQR:
50.0 to 71.0) to week 52 (median: 66.0, IQR: 51.0 to 74.0). In the control
group (n = 11), the median change in BCVA from baseline (median:
63.0, IQR: 53.0 to 69.0) to week 52 (median: 65.0, IQR: 38.0 to 66.5)
was−5.0 (IQR:−17.5 to 1.0) ETDRS letters. The difference in medianchanges between groups was 6.0 ETDRS letters (Fig. 2a and b). In a
post hoc analysis, when the change in BCVA was measured from week
8 (the time point at which gene therapy is believed to potentially take
effect) there was also a difference in median changes between the
gene therapy (median: 1.0, IQR:−4.0 to 10.0 ETDRS letters) and control
groups (median:−12.0, IQR:−17.5 to 2.5 ETDRS letters) at week 52
(Fig. 2c).
Twelve of 21 (57%) gene therapy patients experiencedmaintenance
or improvement of vision versus 4 of 11 (36%) control patients. The per-
centage of patients gaining ≥15 ETDRS letters from baseline to week 52
was 14% (3) for the gene therapy group and 0% for the control group
(Fig. 3). In the gene therapy group 1 patient lost N15 ETDRS letters ver-
sus 3 in the control group. When the 3 control subjects losing 3 lines of
vision (outliers) were removed there was no statistically signiﬁcant dif-
ference in BCVA improvement between the gene therapy and control
groups (Fig. S1). Post hoc analysis of initial lens status showed no
change in average BCVA in the pseudophakic subset atweek 52 suggest-
ing that surgery in the phakic subset only restored vision to pre-cataract
levels (Figs. S2 and S3). There was a signiﬁcant drop in BCVA in the
pseudophakic control group which was due to signiﬁcant loss of vision
in a patient with endophthalmitis and a patient with submacular hem-
orrhage (Fig. S2).
3.6.2. Spectral Domain Optical Coherence Tomography
The SD-OCT images are presented in Fig. S4. In the gene therapy
group (n = 21), a median change in center point thickness (CPT) on
SD-OCT of 5.0 (IQR:−47.0 to 82.0) μm from baseline to week 52 was
observed. In the control group (n = 11), the median change in CPT
was −90.0 (IQR: −173.5 to 64.0) μm (Fig. 2d and e). The difference
in median change in CPT between the gene therapy and control groups
was 95.0 μm. Analyzes of central subﬁeld thickness (CST) showed sim-
ilar results to those for CPT (Fig. S5). There was no clinically important
difference between the median CPT at baseline for the gene therapy
group 328 μm and the control group at 349 μm (Fig. 2c). When the me-
dian change in CPT over time was measured from a new baseline at
week 8, no difference was found between the gene therapy and control
groups at week 52 (Fig. 2d). Similar results were observed for CST (Fig.
S6). Analysis of the SD-OCTs at DIRC demonstrated that results from
manual segmentation and automated segmentation were comparable
(Figs. S7 and S8).
3.6.3. Number of Ranibizumab Retreatments
As a decreased need for ranibizumab retreatment injections would
signal rAAV.sFLT-1 response and disease control, the number of
ranibizumab retreatments performed by week 52 under pre-speciﬁed
criteria was assessed. Excluding the initial 2 mandatory injections in
both groups as per protocol at baseline andweek 4, themedian number
of ranibizumab injections was 2.0 (IQR: 1.0 to 6.0) for the gene therapy
group compared to 4.0 (IQR: 3.5 to 4.0) for the control group (Fig. 4).
Further analysis suggested a negative association between the number
of ranibizumab retreatments and BCVA change in the gene therapy
group (Fig. 5). Eleven (52·4%) rAAV.sFLT-1-treated patients received 2
or fewer ranibizumab retreatments with 3 (14·3%) achieving notable
BCVA gains of ≥15 ETDRS letters. It was also noted that 10 of these 11
(90·9%) patients had nAb to AAV2 present at baseline. The other 10 pa-
tients (47·6%) in the rAAV.sFLT-1-treated group received more than 2
ranibizumab retreatments, with no clinically signiﬁcant vision gain.
Only 2 of these 10 (20%) patients had nAb to AAV2 at baseline. In the
control group, 10 of 11 patients (90·9%) received more than 2
ranibizumab retreatments and none achieved a gain of ≥15 ETDRS let-
ters. Two of the control patients had nAb to AAV2 at baseline.
4. Discussion
This Phase 2a study of 32 patients is the largest ocular AAV clinical
trial to date and serves to conﬁrm the results of the Phase 1 study
Fig. 2.Graphs ofmedian BCVA and CPT over time A:Median BCVA over 52weeks. B:Median change in BCVA from baseline to week 52. C:Median change in BCVA fromweek 8 (activation
of gene therapy) to week 52. D:Median CPT over 52weeks. E:Median change in CPT from baseline toweek 52. F: Median change in CPT fromweek 8 (activation of gene therapy) to week
52. BCVA= Best Corrected Visual Acuity; CPT = Center Point Thickness.
172 I.J. Constable et al. / EBioMedicine 14 (2016) 168–175
Fig. 3. BCVA change category by treatment group. Patients categorized by change in BCVA
at week 52. BCVA= Best Corrected Visual Acuity.
Fig. 5.BCVAvsnumber of ranibizumab retreatments atweek 52. Linear regressionof BCVA
change on the number of ranibizumab retreatments showed a signiﬁcant negative
association (P = 0.01) for Phase 2a gene therapy patients. A subset of rAAV.sFLT-1
treated patients received 2 or fewer ranibizumab retreatments (solid box). A second
subset of rAAV.sFLT-1 treated patients received N2 ranibizumab retreatments (dashed
box). BCVA = Best Corrected Visual Acuity.
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rAAV.sFLT-1 is safe. The study also investigates the potential association
between the safety and patient-focused efﬁcacy of rAAV.sFLT-1 gene
therapy delivered subretinally.
Results of the study showed no serious gene therapy-related ocular
or systemic side effects. All AEs related to gene therapy or study proce-
dureweremild ormoderate and resolvedwithout sequelae. These ﬁnd-
ings were consistent with the Phase 1 study (Rakoczy et al., 2015), as
well as other AAV ocular studies (Vasireddy et al., 2013; Maguire et
al., 2008; Pierce and Bennett, 2015; Simonelli et al., 2010; Testa et al.,
2013). The majority of mild and moderate ocular AEs were associated
with the surgery involving vitrectomy and subretinal injection
(Maguire et al., 2008; Rakoczy et al., 2015). As these procedures were
a necessary component of the AAV therapy, they are an important con-
sideration for safety. A variety of ocular hemorrhages associated with
the surgery were mild in nature without any visual signiﬁcance and
with no permanent sequelae. Cataracts are a known side effect of vitrec-
tomy (Blankenship and Machemer, 1985) and progression to visually
signiﬁcant nuclear cataract in all phakic gene therapy patients and in 1
control patient was noted. It is not yet clear if subretinal injection can
be done safely without vitrectomy. A higher number of systemic AEs
were reported in the gene therapy group compared to the control
group, whichwe interpret as due to the reporting procedures describedFig. 4. Ranibizumab retreatments by treatment group. Distribution of the number of
ranibizumab retreatments in each treatment group, showing the median (thickest line),
the 25th and 75th percentiles (box boundaries), and the range (whiskers).in the Methods section. Respiratory system-related AEs were reported
more frequently in patients treated with rAAV.sFLT-1 (28%) compared
to controls (18%). However, the infections were heterogeneous in char-
acter, and differences in frequency between the gene therapy group and
control group were not statistically signiﬁcant. Overall the incidence of
respiratory system-related AEs in the gene therapy group was less fre-
quent than rates published for existing anti-VEGF agents in late-stage
wAMD trials, so an association with rAAV.sFLT-1 gene therapy seems
unlikely.
Results of rAAV.sFLT-1 qPCR, AAV2 capsid ELISA, and sFLT-1 protein
quantitation indicate that the biodistribution of rAAV.sFLT-1 outside the
target tissue (retina) after subretinal injection is limited and transient.
No rAAV.sFLT-1 DNA or AAV2 capsid were detected in any of the
assessed samples at or after the week 4 visit. The measured systemic
levels of sFLT-1 and VEGF in serum, urine, and saliva were highly vari-
able, ﬂuctuating and dependent on the individual and we could not
identify any trend that would have suggested systemic effect. The only
immune response to rAAV.sFLT-1 therapy detectedwas sero conversion
of nAbs observed in 3 patients which is consistent with previously pub-
lished reports showing that subretinal administration of AAV does not
frequently induce humoral immune responses to the AAV capsid (Li et
al., 2008). Recent reports show that subretinal delivery of rAAV does
not affect the efﬁcacy of rAAV.sFLT-1 therapy when subsequently ad-
ministered to the fellow eye (Li et al., 2008; Bennett et al., 2012).
Amongst the patients who received the rAAV.sFLT-1 gene therapy,
12 (57·1%) had pre-existing nAbs to AAV2 and it seems that pre-
existing nAbs to AAV2 do not necessarily decrease the efﬁcacy of the
gene therapy administered by subretinal injection. This study does not
raise any new concerns for ocular gene therapy with respect to the var-
iables of patient safety and immune response and conﬁrms the pub-
lished work of others (Bennett et al., 2012).
Unlike many of the previously reported anti-VEGF trials (CATT
Research Group et al., 2011; IVAN Study Investigators et al., 2012;
Heier et al., 2012) for wAMD, 29 of 32 (90·6%) recruited patients in
this study were not treatment-naïve, having received a median of 9.0
(IQR: 5.0 to 14.0) previous anti-VEGF injections. The chronic nature of
baseline disease in the patients participating in this safety trial may
have diminished the potential for large vision gains or ﬂuid loss on
SD-OCT. In addition the study was designed to assess the safety of
rAAV.sFLT-1 delivered by subretinal injection and sought to provide
PRN ranibizumab therapy in both arms. Therefore, no signiﬁcant differ-
ence in BCVA and CPT between the gene therapy and control groups
was expected. Nevertheless, the median change in BCVA for the gene
therapy group was+1 · 0 ETDRS letters at week 52, and for the control
174 I.J. Constable et al. / EBioMedicine 14 (2016) 168–175group was −5 · 0 ETDRS letters conﬁrming that rAAVsFLT-1 did not
have a deleterious effect. In the control group, this loss of ETDRS letters
potentially could suggest under-treatment of the wAMD with
ranibizumab, greater intrinsic disease activity or a higher complication
rate for intravitreal injections. However, closer examination reveals
that this loss was due to 3 of 11 (27·3%) patients who lost in excess of
20 ETDRS letters caused by infrequent but well known complications
of the natural history of wAMD and PRN intravitreal therapy. Once
these 3 patients were removed from the analysis there was no statisti-
cally signiﬁcant difference in BCVA improvement between the gene
therapy and the control groups. The incidence of moderate vision loss
was similar in the treatment and control groups suggesting that there
might be a subgroup of patients who do not have the capacity to re-
spond to anti-VEGF treatments. As all the phakic patients in the gene
therapy group required cataract surgery presumed secondary to the ini-
tial vitrectomy, lens status and cataract removal were investigated as
possible explanations for the median ﬁnal BCVA of this group being
higher than the control group. Although the numbers are small, post
hoc analysis of initial lens status and need for cataract surgery was not
found to drive the BCVA in the rAAV.sFLT-1-treated group and the con-
trol group at the week 52 time point.
This study found that the median CPT over time showed a greater
decrease in the control group than the gene therapy group. While
both groups were given ranibizumab injections at baseline and week
4, the gene therapy group patients received a core vitrectomy, associat-
ed with subretinal gene therapy, at day 7. This may have removed any
remaining active ranibizumab from the ﬁrst intravitreal injection, thus
leading to a smaller initial response in the gene therapy group. In
most studies (CATT Research Group et al., 2011; Lalwani et al., 2009),
the greatest decreases in CPT occurred in the ﬁrst 2months of the study.
The gene therapy group had a trend towards fewer ranibizumab
retreatments than the control group, and in a post hoc analysis 11
(53%) gene therapy patients received ≤2 ranibizumab retreatments,
with themajority having improved vision. A cohort of the gene therapy
group received N2 ranibizumab retreatments, but lost or gained b5 let-
ters, suggestive of either under treatment or a bimodal response allud-
ing to either lack of gene therapy effect, less susceptibility to anti-
VEGF therapy, or greater intrinsic disease activity. We were not able to
identify any reliable indicators to suggest a cause for this potential di-
vergent response such as pre-existing immunity to AAV, anti-VEGF re-
sistance, under treatment, variability of successful delivery or the
location of the delivery. Potential reasons for variability between this
Phase 2a study and the previous Phase 1 (Rakoczy et al., 2015) in
BCVA and CPT outcomes were examined (Table S1). Product quality
was evaluated and found to meet drug speciﬁcations in the lots used
in both trials and showed no difference in biologic activity in vitro.
Other possible causes include differing disease stage and anatomic ap-
pearance such as degree of subretinal ﬂuid, geographic atrophy,
subretinal ﬁbrosis, pigment epithelial detachment, and CNV location.
These variations in anatomic appearance and disease stage may also
have impacted certain technical factors of therapy including diffusion
in the retina and subretinal space. In the Phase 1 study, the baselineme-
dian BCVA in ETDRS letters was 40.0 (IQR: 33.0 to 54.0) versus 63.0
(IQR: 50.0 to 71.0) in the Phase 2a patients, while the median CPT was
549.0 (IQR: 268.0 657.0) compared to 332.5 (IQR: 295.5 to 459.8) μm,
respectively. The difference in thickness could have had an impact on
the mobility of sFLT-1 to the area of the subfoveal neovascularization
via changing pharmacokinetic properties (Holash et al., 2002). Other
possibilities are difﬁcult to quantify but may include intrinsic VEGF
load or the degree of anti-VEGF responsiveness in this cohort of pa-
tients. Additional preclinical laboratory studies evaluating potential
sources of variation in the apparent clinical effect between the patients
in this study and our initial report (Rakoczy et al., 2015) using this ap-
proach are underway. These include a determination of the optimal vec-
tor copy number to be injected, the impact of site of injection and the
efﬁcacy of alternative modiﬁed AAV vectors and cDNA constructs.There were several limitations to this study. These include the fact
that this was an open label study as the gene therapy required a surgery
(subretinal injection and vitrectomy) that could not be mimicked by a
sham treatment due to the constraints of a clinical trial. Although the
technicians measuring BCVA were masked, the open label study design
allowed for potential patient or investigator bias. Also, the optimal
method for subretinal administration has not been standardized rela-
tive to both safety and potential efﬁcacy in this patient population
with an anatomically abnormal macula due to intrinsic disease relative
to the normal eye. The retreatment criteria differed slightly from other
published studies (CATT Research Group et al., 2011; Lalwani et al.,
2009), butwere designed to allow for assessment of gene therapy activ-
ity as evidenced by reduced need for ranibizumab retreatments. There
exist a number of different and evolving community standards for
anti-VEGF retreatment including programmed monthly injections,
treat and extend regimens, and PRN regimens. Furthermore, this
Phase 2a study only assessed 1 dose of gene therapy against control,
which prevented an understanding of a possible dose-response effect.
Finally, 29 of 32 patients had previously been treated to varying degrees
for wAMD, in contrast to most wAMD studies that have enrolled only
treatment-naïve patients and that decision may have also affected the
results of the trial.
Based upon the results of this study, rAAV.sFLT-1 is safe when
injected under the retina, but further clinical trials are needed to
prove gene therapy is a viable option for wAMD. Although we per-
formed several post hoc analyzes, the number of patients involved in
the study was too small to make useful assessments of clinical
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